Literature DB >> 24043429

An experimental model of partial insulin-like growth factor-1 deficiency in mice.

I Castilla-Cortazar1, L Guerra, J E Puche, U Muñoz, R Barhoum, E Escudero, J L Lavandera.   

Abstract

Insulin-like growth factor-1 (IGF-1) is responsible for many systemic growth hormone (GH) functions although it has an extensive number of inherent activities (anabolic, cytoprotective, and anti-inflammatory). The potential options for IGF-1 therapy arise as a promising strategy in a wide list of human diseases. However, deeper studies are needed from a suitable animal model. All human conditions of IGF-1 deficiency consist in partially decreased IGF-1 levels since total absence of this hormone is hardly compatible with life. The aim of this work was to confirm that heterozygous Igf-1 (+/-) mice (Hz) may be considered as an appropriate animal model to study conditions of IGF-1 deficiency, focusing on early ages. Heterozygous Igf-1 (+/-) mice were compared to homozygous Igf-1 (+/+) by assessing gene expression by quantitative PCR, serum circulating levels by ELISA, and tissue staining. Compared to controls, Hz mice (25 days old) showed a partial but significant reduction of IGF-1 circulating levels, correlating with a reduced body weight and diminished serum IGFBP-3 levels. Hz mice presented a significant decrease of IGF-1 gene expression in related organs (liver, bone, testicles, and brain) while IGF-1 receptor showed a normal expression. However, gene expression of growth hormone receptor (GHR) was increased in the liver but reduced in the bone, testicles, and brain. In addition, a significant reduction of cortical bone thickness and histopathological alterations in the testicles were found in Hz mice when compared to controls. Finally, the lifelong evolution of IGF-1 serum levels showed significant differences throughout life until aging in mice. Results in this paper provide evidence for considering heterozygous mice as a suitable experimental model, from early stages, to get more insight into the mechanisms of the beneficial actions induced by IGF-1 replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24043429     DOI: 10.1007/s13105-013-0287-y

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  49 in total

1.  Insulin-like growth factor-I, liver function, and hypogonadism in rats with experimentally induced cirrhosis.

Authors:  I Castilla-Cortazar; J Quiroga; J Prieto
Journal:  Hepatology       Date:  2000-06       Impact factor: 17.425

2.  Impaired intestinal sugar transport in cirrhotic rats: correction by low doses of insulin-like growth factor I.

Authors:  I Castilla-Cortazar; J Prieto; E Urdaneta; M Pascual; M Nuñez; E Zudaire; M Garcia; J Quiroga; S Santidrian
Journal:  Gastroenterology       Date:  1997-10       Impact factor: 22.682

Review 3.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

4.  Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth.

Authors:  F Lupu; J D Terwilliger; K Lee; G V Segre; A Efstratiadis
Journal:  Dev Biol       Date:  2001-01-01       Impact factor: 3.582

5.  Altered intestinal transport of amino acids in cirrhotic rats: the effect of insulin-like growth factor-I.

Authors:  M Pascual; I Castilla-Cortazar; E Urdaneta; J Quiroga; M Garcia; A Picardi; J Prieto
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-08       Impact factor: 4.052

6.  Normal growth and development in the absence of hepatic insulin-like growth factor I.

Authors:  S Yakar; J L Liu; B Stannard; A Butler; D Accili; B Sauer; D LeRoith
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

Review 7.  Targeting insulin-like growth factor-1 to treat Alzheimer's disease.

Authors:  Ignacio Torres-Aleman
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

8.  Mitochondrial protection by low doses of insulin-like growth factor- I in experimental cirrhosis.

Authors:  Raquel Pérez; María García-Fernández; Matías Díaz-Sánchez; Juan E Puche; Gloria Delgado; Marian Conchillo; Jordi Muntané; Inma Castilla-Cortázar
Journal:  World J Gastroenterol       Date:  2008-05-07       Impact factor: 5.742

9.  Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver.

Authors:  J F Caro; J Poulos; O Ittoop; W J Pories; E G Flickinger; M K Sinha
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

10.  Liver-derived IGF-I regulates mean life span in mice.

Authors:  Johan Svensson; Klara Sjögren; Jenny Fäldt; Niklas Andersson; Olle Isaksson; John-Olov Jansson; Claes Ohlsson
Journal:  PLoS One       Date:  2011-07-25       Impact factor: 3.240

View more
  11 in total

Review 1.  Regulation of skeletal growth and mineral acquisition by the GH/IGF-1 axis: Lessons from mouse models.

Authors:  Shoshana Yakar; Olle Isaksson
Journal:  Growth Horm IGF Res       Date:  2015-09-28       Impact factor: 2.372

Review 2.  Insulin-like growth factors: actions on the skeleton.

Authors:  Shoshana Yakar; Haim Werner; Clifford J Rosen
Journal:  J Mol Endocrinol       Date:  2018-04-06       Impact factor: 5.098

Review 3.  Effects of GH/IGF axis on bone and cartilage.

Authors:  Manisha Dixit; Sher Bahadur Poudel; Shoshana Yakar
Journal:  Mol Cell Endocrinol       Date:  2020-10-14       Impact factor: 4.102

4.  Altered liver expression of genes involved in lipid and glucose metabolism in mice with partial IGF-1 deficiency: an experimental approach to metabolic syndrome.

Authors:  J Rodríguez De Ita; I Castilla-Cortázar; G A Aguirre; C Sánchez-Yago; M Olleros Santos-Ruiz; L Guerra-Menéndez; I Martín-Estal; M García-Magariño; V J Lara-Díaz; J E Puche; U Muñoz
Journal:  J Transl Med       Date:  2015-10-14       Impact factor: 5.531

5.  Wnt co-receptors Lrp5 and Lrp6 differentially mediate Wnt3a signaling in osteoblasts.

Authors:  Aimy Sebastian; Nicholas R Hum; Deepa K Murugesh; Sarah Hatsell; Aris N Economides; Gabriela G Loots
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240

6.  Partial IGF-1 deficiency is sufficient to reduce heart contractibility, angiotensin II sensibility, and alter gene expression of structural and functional cardiac proteins.

Authors:  José Luis González-Guerra; Inma Castilla-Cortazar; Gabriel A Aguirre; Úrsula Muñoz; Irene Martín-Estal; Elena Ávila-Gallego; Miriam Granado; Juan E Puche; Ángel Luis García-Villalón
Journal:  PLoS One       Date:  2017-08-14       Impact factor: 3.240

7.  Experimental approach to IGF-1 therapy in CCl4-induced acute liver damage in healthy controls and mice with partial IGF-1 deficiency.

Authors:  Luis A Morales-Garza; Juan E Puche; Gabriel A Aguirre; Úrsula Muñoz; Mariano García-Magariño; Rocío G De la Garza; Inma Castilla-Cortazar
Journal:  J Transl Med       Date:  2017-05-04       Impact factor: 5.531

8.  IGF-1 modulates gene expression of proteins involved in inflammation, cytoskeleton, and liver architecture.

Authors:  V J Lara-Diaz; I Castilla-Cortazar; I Martín-Estal; M García-Magariño; G A Aguirre; J E Puche; R G de la Garza; L A Morales; U Muñoz
Journal:  J Physiol Biochem       Date:  2017-01-26       Impact factor: 4.158

9.  IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand.

Authors:  Lucia Guerra-Menéndez; Maria C Sádaba; Juan E Puche; Jose L Lavandera; Luis F de Castro; Arancha R de Gortázar; Inma Castilla-Cortázar
Journal:  J Transl Med       Date:  2013-10-25       Impact factor: 5.531

Review 10.  Is insulin-like growth factor-1 involved in Parkinson's disease development?

Authors:  Inma Castilla-Cortázar; Gabriel A Aguirre; Giovana Femat-Roldán; Irene Martín-Estal; Luis Espinosa
Journal:  J Transl Med       Date:  2020-02-11       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.